What is the 13F Pro Quality Score for CLDX?

13F Pro ranks Celldex Therapeutics, Inc. (CLDX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CLDX's current score at https://13fpro.ai/research/CLDX (free sign-up required for the full ranking).

Where does 13F Pro source CLDX data?

All Celldex Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Celldex Therapeutics, Inc. files with the SEC under CIK 744218. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CLDX in?

Celldex Therapeutics, Inc. (CLDX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CLDX research updated on 13F Pro?

CLDX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Celldex Therapeutics, Inc.(CLDX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 744218 CLDX stock profile & AI dashboard →

13F Pro Quality Score

13.2/100

Rank #2,770 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

4.2/100

Profitability

30.0/100

Balance Sheet

30.0/100

Earnings Quality

30.0/100

Free Cash Flow

0.3/100

Institutional Flow

4.0/100

Revenue Scale

0.7/100

Dilution Risk

0.3/100

CLDX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Celldex Therapeutics, Inc. (CLDX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CLDX at 13.2/100 on a 32-signal composite quality model, placing it at rank #2,770 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (0.3) and revenue scale (0.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Celldex Therapeutics, Inc. reports quarterly revenue of $15.0K, net income of $-78.7M, free cash flow of $-67.2M. Top institutional holders of CLDX by reported 13-F value include WELLINGTON MANAGEMENT GROUP LLP, Kynam Capital Management,, BlackRock,, based on the most recent SEC filings. CLDX trades on the Nasdaq exchange and files with the SEC under CIK 744218. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CLDX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Celldex Therapeutics, Inc. directly from SEC EDGAR. Celldex Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 8 and 60 since 2021, currently 13.2 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

Revenue

Q1 2026

$15.0K

Net Income

Q1 2026

$-78.7M

Free Cash Flow

Q1 2026

$-67.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-78.0% YoY

$1.5MFY 2025

FY20 $7.4MFY21 $4.7MFY24 $7.0MFY25 $1.5M

Net Income

-63.9% YoY

$-258.8MFY 2025

FY20 —FY21 $-70.5MFY24 $-157.9MFY25 $-258.8M

Operating Income

-47.3% YoY

$-287.4MFY 2025

FY20 $-63.4MFY21 $-71.2MFY24 $-195.1MFY25 $-287.4M

EPS (Diluted)

-59.2% YoY

$-3.90FY 2025

FY20 $-2.02FY21 $-1.64FY24 $-2.45FY25 $-3.90

Total Assets

-26.4% YoY

$583.0MFY 2025

FY20 $235.8MFY21 $444.7MFY24 $792.3MFY25 $583.0M

Op. Cash Flow

-33.7% YoY

$-210.9MFY 2025

FY20 $-40.4MFY21 $-60.9MFY24 $-157.8MFY25 $-210.9M

Metric	FY 2025	FY 2024	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	$1.5M -78.0%	$7.0M +50.9%	$4.7M -37.3%	$7.4M +107.6%	$3.6M -62.5%	$9.5M
Net Income	$-258.8M -63.9%	$-157.9M -123.9%	$-70.5M	—	—	—
Operating Income	$-287.4M -47.3%	$-195.1M -173.8%	$-71.2M -12.5%	$-63.4M -15.1%	$-55.0M +64.8%	$-156.4M
EPS (Diluted)	$-3.90 -59.2%	$-2.45 -49.4%	$-1.64 +18.8%	$-2.02 +42.5%	$-3.51	—
Total Assets	$583.0M -26.4%	$792.3M +78.2%	$444.7M +88.5%	$235.8M +91.8%	$122.9M -21.1%	$155.8M
Operating Cash Flow	$-210.9M -33.7%	$-157.8M -159.0%	$-60.9M -50.7%	$-40.4M +13.0%	$-46.4M +38.3%	$-75.2M

AI Insight: CLDX Financial Trends

Celldex is in clinical-stage burn mode with zero revenue, accelerating cash burn, and equity eroding 44% from Q2 2024 to Q1 2026.

• Operating losses expanded from $46M in Q2 2024 to $84M in Q1 2026; operating cash outflow worsened to $66M in latest quarter.

• Shareholder equity collapsed from $814M to $456M over eight quarters; no revenue generation across last four quarters.

• Quarterly operating cash burn accelerated to $66M in Q1 2026 from $29M in Q2 2024, signaling intensifying cash consumption.

⚠ Equity runway: at ~$456M and $66M quarterly burn, ~7 quarters of runway remain without asset sales or financing.

⚠ Net loss hit $81M in Q4 2025 and remained $79M in Q1 2026—no sign of clinical inflection or revenue traction.

AI Insight: CLDX Ratio Trends

ROIC deteriorated sharply to -74.0% in Q1 2026, extending a severe 10-quarter erosion in capital efficiency.

• ROIC collapsed from -22.8% in Q2 2024 to -74.0% in Q1 2026, worsening every quarter. Burning capital at accelerating pace.

• ROE and ROA both plummeted in latest quarter: ROE -69.0%, ROA -61.6%, indicating severe net losses relative to equity and assets.

⚠ ROIC degradation accelerated in Q3 2025–Q1 2026 (three quarters of -49% to -74%), suggesting mounting losses or capital constraints.

⚠ Negative returns across all three metrics (ROE, ROA, ROIC) point to operating losses consuming shareholder capital.

Get alerted when CLDX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Celldex Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CLDX

WELLINGTON MANAGEMENT GROUP LLP
$271.5M8,560,476 sh
Kynam Capital Management, LP
$185.3M5,840,567 sh
BlackRock, Inc.
$170.3M5,369,885 sh
FMR LLC
$118.9M3,749,048 sh
Point72 Asset Management, L.P.
$102.5M3,229,939 sh
VANGUARD CAPITAL MANAGEMENT LLC
$93.9M2,960,895 sh
STATE STREET CORP
$88.9M2,804,168 sh
Commodore Capital LP
$85.5M2,696,616 sh
Eversept Partners, LP
$56.7M1,788,016 sh
GEODE CAPITAL MANAGEMENT, LLC
$53.6M1,688,074 sh

Fund	Value	Shares
WELLINGTON MANAGEMENT GROUP LLP	$271.5M	8,560,476
Kynam Capital Management, LP	$185.3M	5,840,567
BlackRock, Inc.	$170.3M	5,369,885
FMR LLC	$118.9M	3,749,048
Point72 Asset Management, L.P.	$102.5M	3,229,939
VANGUARD CAPITAL MANAGEMENT LLC	$93.9M	2,960,895
STATE STREET CORP	$88.9M	2,804,168
Commodore Capital LP	$85.5M	2,696,616
Eversept Partners, LP	$56.7M	1,788,016
GEODE CAPITAL MANAGEMENT, LLC	$53.6M	1,688,074

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CLDX on your watchlist

Track score changes the day Celldex Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CLDX a good stock to buy?

13F Pro's AI-powered analysis of Celldex Therapeutics, Inc. (CLDX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CLDX are available on the CLDX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CLDX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CLDX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Celldex Therapeutics, Inc.'s investment landscape.